Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Year: 1996
Type: article
Source: PubMed
Institutions: National Institutes of Health, National Cancer Institute
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1500051268
